Zhaboyedova N. Cerebroprotective activity of ademol in experimental intracranial hemorrhage

The dissertation is devoted to the solution of the actual problem of pharmacology, which is to increase the effectiveness of neuroprotection in hemorrhagic stroke on the basis of experimentally justified feasibility and possibility of using a new purpose NMDA receptor blocker ampoule 1.0% solution of 1-adamantylthyloxy-3-morpholino-2- propanol hydrochloride (ademol). Glutamate excitotoxicity, which is mediated by excessive overexcitation of NMDA receptors, deficiency intraneuronal energy supply, changes oxidant-antioxidant balance, acid-base regulation equilibrium, nitric oxide metabolism – all this is promising the way in which the primary pharmacological development should be carried out cerebrorotector program, in particular by expanding the readings to the application of already known and registered in the State pharmacological center of drugs with NMDA-modulating action for a new purpose. Such a drug can be as follows adamantane derivative as 1-adamantylthyloxy-3-morpholino-2-propanol hydrochloride – ademol, which is produced from finished chemical raw materials "in bulk" on the basis of production facilities of PJSC "Pharmaceutical company "Darnytsia" (Kyiv, Ukraine). In terms of these properties, ademol probably exceeded the effectiveness of amantadine and magnesium sulfate. Using the method of chemoinformatics, it was found that ademol has a high bioavailability, which provides the possibility of intravenous administration, it freely penetrates the blood-brain barrier, which is associated with satisfactory medicinal properties.